NCT02340975: A reported trial by MedImmune LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02340975 |
|---|---|
| Title | A Phase 1b/2 Study of MEDI4736 in Combination With Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 31, 2015 |
| Completion date | April 29, 2019 |
| Required reporting date | April 28, 2020, midnight |
| Actual reporting date | April 27, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |